Norges Bank Makes New $116.80 Million Investment in BridgeBio Pharma, Inc. $BBIO

Posted by Brenda Bartman on Jun 5th, 2026

Norges Bank purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,527,028 shares of the company’s stock, valued at approximately $116,802,000.

Several other institutional investors have also recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the 3rd quarter worth approximately $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the 1st quarter worth approximately $35,000. Huntington National Bank boosted its holdings in BridgeBio Pharma by 111.7% in the third quarter. Huntington National Bank now owns 743 shares of the company’s stock worth $39,000 after acquiring an additional 392 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after acquiring an additional 245 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the subject of several recent research reports. Morgan Stanley boosted their price objective on BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Truist Financial increased their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Barclays reissued an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, Mizuho reaffirmed an “outperform” rating and issued a $106.00 price objective on shares of BridgeBio Pharma in a research note on Tuesday, April 28th. Twenty-three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.59.

Get Our Latest Research Report on BridgeBio Pharma

Insiders Place Their Bets

In other BridgeBio Pharma news, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $67.15, for a total value of $671,500.00. Following the transaction, the director owned 11,589 shares of the company’s stock, valued at approximately $778,201.35. The trade was a 46.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $65.08, for a total value of $888,407.08. Following the completion of the transaction, the chief financial officer owned 359,194 shares of the company’s stock, valued at $23,376,345.52. This trade represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 171,754 shares of company stock valued at $11,965,659. Insiders own 14.23% of the company’s stock.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $67.33 on Friday. BridgeBio Pharma, Inc. has a fifty-two week low of $37.69 and a fifty-two week high of $84.94. The firm’s 50-day simple moving average is $70.78 and its 200 day simple moving average is $72.10. The stock has a market cap of $13.19 billion, a PE ratio of -18.00 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.52 million for the quarter, compared to analysts’ expectations of $178.07 million. During the same period last year, the business posted ($0.88) EPS. The business’s revenue was up 66.8% on a year-over-year basis. As a group, analysts predict that BridgeBio Pharma, Inc. will post -2.32 EPS for the current fiscal year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.